BiotechReality – Covering Industry, Business, and Academia
Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.
Athulya B S
11 June 2025
Novo Nordisk keeps pushing the boundaries of obesity innovation by revealing the whole Phase 3 REDEFINE 1 and 2 trial data, which shed light on CagriSema’s revolutionary potential.
Editor's Desk
10 March 2025
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
A SciRealityPress Associate
Contents in the website is licensed under CC BY-NC 4.0
Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio